- Home
- MQT vs ADCT Comparison
MQT vs ADCT Comparison
Compare MQT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- ADCT
- Stock Information
- Founded
- MQT 1992
- ADCT 2011
- Country
- MQT United States
- ADCT Switzerland
- Employees
- MQT N/A
- ADCT N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- ADCT Health Care
- Exchange
- MQT Nasdaq
- ADCT Nasdaq
- Market Cap
- MQT 210.8M
- ADCT 241.0M
- IPO Year
- MQT N/A
- ADCT 2020
- Fundamental
- Price
- MQT $9.67
- ADCT $2.88
- Analyst Decision
- MQT
- ADCT Strong Buy
- Analyst Count
- MQT 0
- ADCT 6
- Target Price
- MQT N/A
- ADCT $7.80
- AVG Volume (30 Days)
- MQT 52.5K
- ADCT 915.5K
- Earning Date
- MQT 01-01-0001
- ADCT 08-05-2025
- Dividend Yield
- MQT 4.60%
- ADCT N/A
- EPS Growth
- MQT N/A
- ADCT N/A
- EPS
- MQT N/A
- ADCT N/A
- Revenue
- MQT N/A
- ADCT $75,817,000.00
- Revenue This Year
- MQT N/A
- ADCT $10.65
- Revenue Next Year
- MQT N/A
- ADCT $15.05
- P/E Ratio
- MQT N/A
- ADCT N/A
- Revenue Growth
- MQT N/A
- ADCT 10.49
- 52 Week Low
- MQT $8.59
- ADCT $1.05
- 52 Week High
- MQT $10.67
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- MQT 59.65
- ADCT 51.19
- Support Level
- MQT $9.51
- ADCT $2.55
- Resistance Level
- MQT $9.58
- ADCT $2.88
- Average True Range (ATR)
- MQT 0.06
- ADCT 0.25
- MACD
- MQT 0.03
- ADCT -0.09
- Stochastic Oscillator
- MQT 88.00
- ADCT 21.13
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).